DE60119714D1 - Peptidderivat - Google Patents

Peptidderivat

Info

Publication number
DE60119714D1
DE60119714D1 DE60119714T DE60119714T DE60119714D1 DE 60119714 D1 DE60119714 D1 DE 60119714D1 DE 60119714 T DE60119714 T DE 60119714T DE 60119714 T DE60119714 T DE 60119714T DE 60119714 D1 DE60119714 D1 DE 60119714D1
Authority
DE
Germany
Prior art keywords
function regulator
regulator
development
present
peptide derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60119714T
Other languages
English (en)
Other versions
DE60119714T2 (de
Inventor
Chieko Kitada
Naoki Nishizawa
Shuji Hinuma
Masaki Hosoya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of DE60119714D1 publication Critical patent/DE60119714D1/de
Application granted granted Critical
Publication of DE60119714T2 publication Critical patent/DE60119714T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
DE60119714T 2000-03-23 2001-03-22 Peptidderivat Expired - Lifetime DE60119714T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000087114 2000-03-23
JP2000087114 2000-03-23
JP2000288891 2000-09-19
JP2000288891 2000-09-19
PCT/JP2001/002278 WO2001070769A1 (fr) 2000-03-23 2001-03-22 Derive peptidique

Publications (2)

Publication Number Publication Date
DE60119714D1 true DE60119714D1 (de) 2006-06-22
DE60119714T2 DE60119714T2 (de) 2006-09-07

Family

ID=26588465

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60119714T Expired - Lifetime DE60119714T2 (de) 2000-03-23 2001-03-22 Peptidderivat

Country Status (10)

Country Link
US (1) US7635751B2 (de)
EP (1) EP1270585B1 (de)
JP (1) JP4786047B2 (de)
KR (1) KR20020081466A (de)
CN (1) CN1419563A (de)
AT (1) ATE326478T1 (de)
AU (1) AU2001242749A1 (de)
CA (1) CA2403447A1 (de)
DE (1) DE60119714T2 (de)
WO (1) WO2001070769A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063892A1 (fr) * 2002-01-29 2003-08-07 Takeda Chemical Industries, Ltd. Utilisation d'apeline
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
EP1967210A4 (de) * 2005-12-20 2009-11-11 Takeda Pharmaceutical Neue anwendung von apelin
RU2303454C1 (ru) * 2006-06-22 2007-07-27 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Средство, нормализующее репродуктивную функцию у женщин, и способ его получения
EP1903052A3 (de) * 2006-07-28 2008-04-02 Faust Pharmaceuticals SA APJ Rezeptor-Liganden und deren Verwendung
WO2013050441A1 (en) 2011-10-05 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
ES2638649T3 (es) 2011-11-28 2017-10-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Composición farmacéutica para su uso en el tratamiento de disfunciones asociadas al envejecimiento
CA2860740A1 (en) * 2012-01-09 2013-07-18 Anchor Therapeutics, Inc. Apj receptor compounds
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
EP3907237A1 (de) 2012-12-20 2021-11-10 Amgen Inc. Apj-rezeptor-agonisten und verwendungen davon
CN105705167A (zh) 2013-07-25 2016-06-22 诺华股份有限公司 合成的apelin多肽的生物缀合物
EP3024845A1 (de) 2013-07-25 2016-06-01 Novartis AG Cyclische polypeptide zur behandlung von herzinsuffizienz
CN104436158A (zh) * 2013-09-22 2015-03-25 华中科技大学 Apelin-13在治疗糖尿病肾病中的应用
GB201407532D0 (en) * 2014-04-29 2014-06-11 Univ Ulster Apelin analogues
JP2018507187A (ja) 2015-01-23 2018-03-15 ノバルティス アーゲー 改善された半減期を有する合成アペリン脂肪酸コンジュゲート
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
HUE050317T2 (hu) 2015-05-20 2020-11-30 Amgen Inc APJ receptor triazol agonistái
WO2017140684A2 (en) 2016-02-15 2017-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
US10736883B2 (en) 2016-11-16 2020-08-11 Amgen Inc. Triazole furan compounds as agonists of the APJ receptor
EP3541804A1 (de) 2016-11-16 2019-09-25 Amgen Inc. Cycloalkyl-substituierte triazolverbindungen als agonisten des apj-rezeptors
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE164884T1 (de) * 1992-11-17 1998-04-15 Icos Corp Neue sieben-transmembran-rezeptor v28
DE69838986T2 (de) * 1997-12-24 2009-01-08 Takeda Pharmaceutical Co. Ltd. Polypeptide, deren herstellung und verwendung
US6475718B2 (en) * 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
AU5759399A (en) * 1998-09-25 2000-04-17 Takeda Chemical Industries Ltd. Peptide derivative

Also Published As

Publication number Publication date
EP1270585B1 (de) 2006-05-17
EP1270585A4 (de) 2004-12-15
WO2001070769A1 (fr) 2001-09-27
EP1270585A1 (de) 2003-01-02
KR20020081466A (ko) 2002-10-26
JP4786047B2 (ja) 2011-10-05
US20040116336A1 (en) 2004-06-17
ATE326478T1 (de) 2006-06-15
CA2403447A1 (en) 2001-09-27
US7635751B2 (en) 2009-12-22
AU2001242749A1 (en) 2001-10-03
DE60119714T2 (de) 2006-09-07
JP2002167397A (ja) 2002-06-11
CN1419563A (zh) 2003-05-21

Similar Documents

Publication Publication Date Title
ATE326478T1 (de) Peptidderivat
SE9901379D0 (sv) Receptor structures
SE8904087L (sv) Peptide derivates
DE69638023D1 (de) Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
DE60025832D1 (de) Mehrere zytokin-antikörper komplexen
ATE352559T1 (de) Verfahren zur verminderung der immunogenität von proteinen
DE69633175D1 (de) Multimere proteine
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
DE69906108T2 (de) Peptid-derivat
DE69636437D1 (de) Ligand polypeptide für hypophyse g-protein gekoppeltes rezeptor-protein, deren herstellung und anwendung
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
MXPA02008239A (es) Gen humano de la esquizofrenia.
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
PT996726E (pt) Proteina de membrana de celulas t (tirc7) peptidos e anticorpos dela derivados e suas utilizacoes
ATE164838T1 (de) Neue propoxyphenderivate sowie deren protein-und polypeptidlabels und-konjugate
EP0716591A4 (de) Verfahren und Präparat zum Binden von TAU und MAP2c Proteinen
ATE196775T1 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
DE60330680D1 (de) Transferrin-fusionsproteinbibliotheken
WO1999042127A3 (en) Receptor derived peptides as modulators of receptor activity
WO2001064876A3 (en) Human schizophrenia gene
DE69611037T2 (de) Methadonderivate und protein- und polypeptid-methadonkonjugate und markierte verbindungen
DK0972781T3 (da) Protein S-polypeptider og anvendelser deraf
DE69712182D1 (de) Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises
TR200002611T2 (tr) Beta-lipotropin ve kullanımları

Legal Events

Date Code Title Description
8364 No opposition during term of opposition